India, March 26 -- ViiV Healthcare, a global specialist HIV company majority-owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, Wednesday announced that APRETUDE (cabotegravir tablets and extended-release injectable suspension) is now included in Canada's Non-Insured Health Benefits (NIHB) Program.
This coverage will make APRETUDE accessible for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at-risk individuals who are HIV-negative.
The NIHB Program provides First Nations and Inuit people with access to health benefits not covered by private, provincial, or territorial insurance. Despite representing only 5% of Canada's population, Indigenous communities account f...